Sun Pharma unit inks licensing pact with US-based firm to introduce drug to treat stroke
"The Phase 3 clinical trial for Tyvalzi conducted in India demonstrated statistically and clinically meaningful improvement in neurological outcomes in ischemic stroke," Sun Pharma India Business CEO Kirti Ganorkar said. Tyvalzi is a first-in-class innovative drug which can help improve the quality of life of stroke patients, he added.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Brain | Clinical Trials | India Health | Ischemic Stroke | Neurology | Pharmaceuticals | Statistics | Stroke